35 results about "Metastasis model" patented technology

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The application specifically relates to a breast cancer invasion and metastasis model based on anisotropic collagen hydrogel and a construction method thereof, and belongs to the technical field of biomedical materials and tumor microenvironment. The anisotropic hydrogel with highly parallel arrangement of collagen fibers is prepared by adopting a PDMS mold pre-tensioning-stress rebound process, and the orientation index is 0.62+ / -0.05. The hydrogel has high matching of mechanical properties with the breast cancer microenvironment in vivo and good biocompatibility. The model can induce mature adipocytes to dedifferentiate and fibroblasts to transdifferentiate, and drive the breast cancer cells to have enhanced invasion and migration ability and EMT phenotype, and reproduce a pathological axis of "collagen orientation→adipocyte dedifferentiation→breast cancer invasion and metastasis". The process depends on the activation of a DDR1-integrin beta1-FAK-YAP signal path, and a DDR1 inhibitor can effectively reverse the above effects. The application can be used for breast cancer metastasis mechanism research and drug screening targeting the DDR1 path.

The invention belongs to the technical field of new applications of medicines, and particularly relates to an aniline pyridine TEAD degradation agent, a preparation method thereof and an application of the degradation agent in preparation of antitumor drugs. According to the research, a novel aniline pyridine TEAD degradation agent with a clear structure is designed and synthesized by coupling a TEAD palmitoylation inhibitor niflumic acid serving as a lead compound with a CRBN type E3 ligase ligand through connecting chains with different lengths and different types by virtue of a computer-aided drug design means. The influence of the optimal compound (XY-3L) on cancer cell proliferation and cell functions is detected in an in-vitro cell experiment, and the curative effect of the optimal compound (XY-3L) in a melanoma lung metastasis model is explored in vivo.

The application discloses application of pachymic acid B in preparation of a medicine for preventing peritoneal metastasis of gastric cancer and a medicine composition thereof. The pachymic acid B is chemically named as 3-O-acetyl-16alpha-hydroxydehydrotrametenolic acid. The in-situ transplantation peritoneal metastasis model of the gastric cancer proves that intraperitoneal injection of the pachymic acid B can significantly reduce the number of peritoneal metastasis nodules and tumor load, the prevention effect is equivalent to that of oxaliplatin, and there is no obvious organ toxicity. Further experiments prove that the pachymic acid B can up-regulate the mRNA and protein expression levels of SPRED2 genes in peritoneal tissues of the gastric cancer, and plays a role in a time-dose dependent manner. The pachymic acid B provided by the application is administered by intraperitoneal injection, can be prepared into a suspension containing sodium carboxymethyl cellulose, and is especially suitable for perioperative administration of gastric cancer primary focus resection. Compared with the prior art, the application has the advantages of clear composition, novel action mechanism, high safety, simple operation, strong accessibility and the like.

The invention relates to the technical field of biological medicines, in particular to application of four micro RNAs (Ribonucleic Acid) of miR-92a, miR-25, miR-30d and miR-30c and inhibitors targeting the four micro RNAs to preparation of medicines for resisting metastasis of multiple cancer species such as breast cancer, colorectal cancer and melanoma. When the nucleic acid inhibitor anti-agomirs targeting at least one of a set consisting of miR-92a, miR-25, miR-30d and miR-30c is used for treating metastasis of multiple cancer species, the anti-metastasis effect is remarkable, the universality is high, and the nucleic acid inhibitor anti-agomirs can show a strong inhibition effect in three different tumor metastasis models of breast cancer, colorectal cancer and melanoma; especially, when the four inhibitors are combined for use, the synergistic effect is prominent, the colorectal cancer liver metastasis load can be reduced by 90% or above, the breast cancer metastasis rate is reduced by 80% or above, the melanoma metastasis inhibition rate is 65% or above, and the composition is suitable for treatment of multi-cancer metastasis.

The present application relates to the field of animal model construction, and in particular to a melanoma liver metastasis model construction method, which uses a spleen injection method to construct a human melanoma A375-M1 cell line liver metastasis model, and is identified in vivo by PET-CT and MRI, and is identified ex vivo by Bouin's and H&E.The human melanoma liver metastasis tumor model constructed by the present application has the advantages of short construction time, simple method and 100% modeling success rate.This metastasis model simulates the development process and pathological characteristics of melanoma liver metastasis, solves the problem of the lack of an ideal animal model for human melanoma during liver metastasis, and helps to explore and screen the development of anti-liver metastasis drugs for human melanoma, and plays a positive promoting role in new strategies for anti-melanoma liver metastasis.

The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.

This invention discloses a wasp venom peptide-M nanocomposite, its preparation method, and its applications, belonging to the field of medicinal chemistry. Using indocyanine green as a morphology mediator, this invention prepares an ultra-small particle size dendritic tetrasulfide by reacting it with triethylamine, hexadecyltrimethylammonium bromide, tetraethyl orthosilicate, and bis[3-(triethoxysilyl)propyl]tetrasulfide in water. Wasp venom peptide-M is then loaded onto this nanocomposite to obtain the wasp venom peptide-M nanocomposite. In vitro experiments have confirmed that this composite can significantly kill 4T1 breast cancer cells. Furthermore, thanks to its ultra-small particle size, it also exhibits good targeting and enrichment, significant anti-tumor efficacy, and excellent safety in a breast cancer brain metastasis model, providing a novel and efficient nanomedicine delivery system for brain tumor treatment and the development of related therapeutic drugs.

The utility model relates to the technical field of tumor cell metastasis models, in particular to a breast cancer circulating tumor cell remote metastasis model which comprises a base and a fixing rod, the fixing rod is fixedly connected to the base, the fixing rod is fixedly connected with a brain metastasis model, a placing component is installed on the brain metastasis model, and the placing component is fixedly connected with the brain metastasis model. The placing part comprises an inclined plate, a fixed plate, a movable plate, a pressed plate, a straight spring and a collecting box, the inclined plate is fixedly connected in the brain metastasis model, the clamping plate clamps small balls with different colors through the matching effect of the extrusion rod, the movable plate, the collecting box and other parts, the small balls can be taken out by pulling the clamping plate, and the small balls can be conveniently taken out. And residual water is left in the collecting box, so that the small balls can be quickly taken out, meanwhile, no water drips on the outer surface of the model, the situation that the transparency of the model is affected by water marks generated on the outer surface of the model due to water dripping is avoided, and the transparency of the organ model and the cleanliness of a placement environment are guaranteed.

The present invention relates to a method for constructing a mouse colorectal carcinoma in situ model, comprising the following steps: fixing an anesthetized mouse under a stereomicroscope, pulling out the mouse's colon and rectum under light, injecting colorectal cancer cells into the colorectal submucosal membrane, pressing to stop bleeding after the injection, returning the colon and rectum to the abdominal cavity and waiting for the mouse to wake up, thereby constructing a mouse colorectal carcinoma in situ model. The animal model obtained by the present invention has significantly reduced mortality and infection rates during and after surgery, and truly achieves in situ implantation. After the tumor cells are injected into the target organ, there is no metastasis phenomenon at all. Based on this, the carcinoma in situ model, especially when used as a colorectal cancer metastasis model, obtains more accurate and reliable results, has higher reference value, and has advantages that cannot be matched by existing technologies.

The application discloses an IGF2BP2-m6A-VCAN-TLR2 signal axis in the preparation of a drug for treating intrahepatic cholangiocarcinoma lymphatic metastasis. In view of the problems of unknown intrahepatic cholangiocarcinoma lymphatic metastasis mechanism and lack of effective target, the application finds and verifies a new pathway that from insulin-like growth factor 2 mRNA binding protein 2, m6A modification regulates the expression of multi-functional proteoglycan, and then activates Toll-like receptor 2 signal, promotes macrophage secretion of vascular endothelial growth factor C and drives lymphatic metastasis. Based on this, the application provides an inhibitor targeting the signal axis, in particular, a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit cholangiocarcinoma cell migration, invasion and epithelial mesenchymal transition, reduce macrophage secretion of vascular endothelial growth factor C, and effectively inhibit tumor growth and lymphatic metastasis in a naked mouse popliteal lymph node metastasis model and a spontaneous cholangiocarcinoma model. The compound presents a synergistic effect in combination with gemcitabine and cisplatin.

The invention discloses a construction method of a breast cancer cell line and lung organ co-culture model, and belongs to the technical field of construction of breast cancer lung metastasis models. Through two innovative designs of a three-dimensional matrix supporting structure and gradient inoculation time sequence control, direct interaction simulation of cancer cells and organoids is realized. Breast cancer cell-lung tissue three-dimensional space interaction is simulated through direct co-culture, the physiological correlation is improved, and the method is superior to Transwell indirect contact. The technology is simplified, complex equipment is not needed, and the operation threshold is lowered through static culture. The construction of the co-culture model can support transfer mechanism research and individualized drug sensitivity test. The breast cancer cells and the organoid are mixed according to the proportion of 10: 1, staged fluid infusion can prevent fluid shear force from damaging the structure of the organoid, meanwhile, the physiological process of tumor progressive invasion is simulated, the breast cancer is preferentially attached to the basement membrane under low nutrition pressure, and subsequent fluid infusion induces the breast cancer to migrate to the high nutrition area of the organoid.

The present invention belongs to the field of medical technology, and relates to a hypoxia-responsive bionic nano-delivery system, a preparation method and a use thereof. The delivery system of the present invention uses polyethylene glycol-polylysine hypoxia-responsive copolymer as a nano-core, and wraps a cell membrane in the outer layer of the nano-core by thin film extrusion technology. The hypoxia-responsive bionic delivery system can encapsulate hydrophobic drugs, and its particle size is uniform and stable, the encapsulation rate is good, and it also has good hypoxia response characteristics. Cell experiments show that the hypoxia-responsive bionic delivery system is more easily taken up by 4T1 cells. Animal experimental results show that the delivery system has good targeting in the triple-negative breast cancer lung metastasis model, and can inhibit the growth and lung metastasis of in situ tumors in the triple-negative breast cancer model.

The present invention relates to a method for constructing and validating a high-metastasis model of colorectal cancer, and belongs to the field of biotechnology. Specifically, the present invention applies in vitro and in vivo selective evolutionary pressure to a colorectal cancer cell line (LoVo) to obtain a cell line (LoVo-HM) CCTCC NO: C2024232 with high metastasis ability; the screened LoVo-HM cell line and the LoVo cell line are verified using in vitro migration and invasion experiments and in vivo tumorigenesis experiments in animals, proving that the model was successfully established. The LoVo-HM cell line constructed by the present invention has strong migration, invasion and metastasis abilities, providing a new vector for the study of the mechanism of colorectal cancer liver metastasis.

The invention provides a lung cancer cell LLC-ML2 as well as an establishment method and application thereof. The lung cancer cells are used for highly expressing CD18 molecules, Strc molecules, Cd79a molecules, Amigo2 molecules, Plet1 molecules, Angptl4 molecules and Plac1 molecules; ddx3y, Cbr3, Sox11, Pid1, Kdm5d, Eif2s3y and Capn6 molecules are not expressed or are subjected to low expression. The LLC cell strain is obtained by inoculating common LLC cells to a C57BL / 6 mouse, taking a lung metastatic focus for culture, inoculating primarily cultured metastatic focus cells to the C57BL / 6 again, taking the lung metastatic focus for different clone culture, and screening. Through two times of lung metastatic focus tumorigenesis and screening, compared with LLC cells, the lung cancer cells are shorter in use time for constructing a metastasis model, and the metastasis rate of main organs is higher; an efficient cell model is provided for better researching a tumor invasion and metastasis mechanism.

This invention relates to the field of animal model construction, specifically a method for constructing a lung metastasis model of the human melanoma A375-M1 cell line. The human melanoma A375-M1 cell line lung metastasis model was constructed using tail vein injection, and in vivo identification was performed using PET-CT and MRI, while in vitro identification was performed using Bouin's and H&E assays. The human melanoma lung metastasis model constructed by this invention has the advantages of short construction time, simple method, and 100% modeling success rate. This metastasis model simulates the development process and pathological characteristics of melanoma lung metastasis, solving the problem of the lack of ideal animal models for human melanoma lung metastasis. It contributes to the exploration and screening of anti-lung metastasis drugs for human melanoma and plays a positive role in promoting new strategies for combating melanoma lung metastasis.

The invention relates to a construction method and application of a colorectal cancer liver metastasis cell strain, and the construction method specifically comprises the following steps: transfecting a tdToma / Luciferase gene to CT26. WT to obtain a CT26-TL cell strain; the colorectal cancer cell strain capable of directionally and stably transferring the liver is obtained by taking a CT26-TL cell strain as a starting material and carrying out three rounds of spleen injection screening and five rounds of cecum injection screening, the colorectal cancer cell strain is named as a mouse colorectal cancer cell clone strain CT26-TL-CL5, and the preservation number is CCTCC NO: C2024307. According to the CT26-TL-CL5 cell strain, the technical difficulty of constructing a liver metastasis model starting from in situ in basic research is solved, the problem of observing colorectal cancer liver metastasis in a living body or an isolated organ is solved, and the modeling time is effectively shortened. The CT26-TL-CL5 cell strain can provide a good colorectal cancer liver metastasis animal model for researching molecules and mechanisms for promoting colorectal cancer liver metastasis, and provides cells and related animal models for industrially screening drugs related to colorectal cancer metastasis.

The invention provides an establishment method of a gastric cancer liver metastasis PDX model, and belongs to the technical field of PDX model establishment. The establishment method of the stomach cancer liver metastasis PDX model comprises the following steps: collecting stomach cancer tissues of a clinical patient, and preprocessing the stomach cancer tissues; cutting the gastric cancer tissue into gastric cancer tissue cubes and storing the gastric cancer tissue cubes; the method comprises the following steps: shaving and preparing abdominal skin of a mouse, disinfecting, transversely cutting the skin and peritoneum of the mouse by using sterile dissecting scissors, and exposing large-lobe tissue of the liver; a sterile syringe needle is used for creating a tiny wound on the liver lobe scratch; suturing the gastric cancer tissue cubes to the tiny wounds; and the peritoneum and skin of the mouse are sutured by absorbable surgical sutures. Compared with a gastric cancer liver metastasis model constructed by a cell line, the model obtained by the method for establishing the gastric cancer liver metastasis PDX model is closer to tumor tissue characteristics, genetic hereditary characteristics and tumor heterogeneity of a patient, and is more beneficial to individualized treatment or mechanism research of the patient.

The present application relates to the field of biotechnology, in particular, the application of E4BP4 in hematological diseases such as multiple myeloma. The present application proves that E4BP4 can be used as a potential biomarker and prognostic indicator for predicting the development of multiple myeloma, which is helpful for the treatment of multiple myeloma. Moreover, the E4BP4 protein can be used in the preparation of MM promoting reagents, which can be further used in the amplification of MM cells, the preparation of MM tumor metastasis models, the screening of MM treatment drugs and the like. After knocking down E4BP4, autophagy is induced and MM cell apoptosis is promoted, thereby enhancing the anti-myeloma effect of dexamethasone on MM. E4BP4 inhibitory drugs can be used as anti-myeloma drugs together with dexamethasone.

The invention discloses a cell strain A375-H for constructing a melanoma liver metastasis model as well as a construction method and application of the cell strain A375-H, and relates to the technical field of biology, and the preservation number of the cell strain A375-H is CGMCC No.46344. The cell strain is classified and named as an A375 high metastatic melanoma cell strain. The A375-H cell strain with high metastatic property and liver metastatic potential is efficiently and conveniently obtained by adopting a continuous 10-round Transwell screening combined monoclonal cell selection method. The A375-H cell strain has high liver metastasis invasion potential, and a unique seed cell model is provided for researching the liver metastasis mechanism of melanoma.

The invention discloses a pharmaceutical composition, which contains carboxamide triazole and bisphosphate which have the same or different specifications and are administered simultaneously or respectively, and the bisphosphate is at least one of clodronate sodium, alendronate sodium, risedronate sodium and zoledronic acid. Researches show that the anti-tumor and anti-inflammatory effects of the carboxamidotriazole combined with the diphosphate are better than those of single drugs DES and ZOA; meanwhile, compared with the single administration of the zoledronic acid with the concentration of 0.1 mg / kg or the single administration of the CAI with the concentration of 40 mg / kg and 80 mg / kg, the combined administration of the zoledronic acid with the concentration of 0.1 mg / kg and the combined administration of the CAI with the concentration of 40 mg / kg and 80 mg / kg can significantly inhibit the growth and proliferation of human lung cancer A549-luc xenotransplantation tumors in bone metastasis of B-NDG mice, and has an unexpected combined synergistic effect. And the zoledronic acid and CAI combined administration group can significantly prolong the survival time of the human lung cancer A549-luc cells in a non-small cell lung cancer bone metastasis model animal established in a B-NDG mouse. The traditional Chinese medicine composition has the effects of remarkable combined synergism and less toxic and side effects.

The present application relates to a breast cancer bone metastasis mouse model construction method, and belongs to the field of mouse tumor metastasis model construction. First, breast cancer cells are induced into a chemotherapy-resistant persistent state. Then, the culture supernatant of the breast cancer chemotherapy-resistant persistent state cells is continuously injected into the recipient mice for 14 days to create a pre-bone metastasis microenvironment of breast cancer. Finally, the breast cancer chemotherapy-resistant persistent state cell line is transplanted into the recipient mice by intra-iliac artery injection, and the formation of bone metastasis foci in the transplanted mice can be monitored about 14 days later. The modeling method of the present application has high tumor metastasis specificity, tumor formation rate and mouse survival rate. In addition, the present application is closer to the pathological occurrence process of clinical breast cancer bone metastasis, and has broad basic scientific research value.

The application provides lung cancer cells and a method for establishing the same and application. The lung cancer cells highly express CD18, Strc, Cd79a, Amigo2, Plet1, Angptl4 and Plac1 molecules; do not express or lowly express Ddx3y, Cbr3, Sox11, Pid1, Kdm5d, Eif2s3y and Capn6 molecules. The lung cancer cells are obtained by inoculating common LLC cells into C57BL / 6 mice, culturing lung metastatic foci, inoculating the primary cultured metastatic foci cells into C57BL / 6 again, culturing different clones of lung metastatic foci again, and screening. After twice lung metastatic foci tumorigenesis and screening, compared with LLC cells, the lung cancer cells are shorter in use time for constructing a metastasis model, and higher in metastasis rate of main organs; and the lung cancer cells provide a high-efficiency cell model for better studying the mechanism of tumor invasion and metastasis.

The application belongs to the field of biological medicine, and relates to application of chondroitin acid protein 1 in preparation of a reagent for diagnosing lung adenocarcinoma or evaluating lung adenocarcinoma prognosis. The application screens CRTAC1 from a GEO database through bioinformatics analysis and a machine learning algorithm, and the CRTAC1 is significantly lowly expressed in lung adenocarcinoma tissues, and an AUC reaches 0.972. Verification of a GEPIA database shows that low expression of the CRTAC1 is significantly related to poor prognosis such as advanced pathological stages, and a patient with high expression has better prognosis. The CRTAC1 blocks epithelial-mesenchymal transition through inhibition of an EGF / ErbB signal path, and remodels a tumor immune microenvironment through inhibition of M2 type macrophage polarization. A mouse lung metastasis model proves that overexpression of the CRTAC1 significantly reduces lung metastasis nodules. The application provides a new molecular marker and a drug target for early diagnosis, prognosis evaluation and precise treatment of lung adenocarcinoma.

The invention belongs to the technical field of biomedicine, and relates to the technical field of neurology, immunology and transgenosis in biomedicine, in particular to an adoptive metastasis model of mice with optic neuromyelitis pedigree diseases and a method for establishing the adoptive metastasis model of the mice with optic neuromyelitis pedigree diseases. The invention further discloses application of the adoptive metastasis model of the mouse with the neuromyelitis optica pedigree disease. According to the application, the Tfh cells are used for adoptively transferring mice to construct a new NMOSD mouse model, and a support basis is provided for exploring the effect of the AQP4 reactive Tfh cells in the NMOSD pathogenesis by evaluating the phenotype and pathology of the new NMOSD mouse model. The model can also become a tool for screening treatment targets for treating the neuromyelitis optica pedigree disease.

The invention relates to application of circular RNA (Ribonucleic Acid) as a colorectal cancer biomarker and a treatment target. In-vivo and in-vitro experiments prove that the migration ability of colorectal cancer cells is remarkably improved in a high-fat environment so as to promote the colorectal cancer process. The circ-PRKACB with remarkably increased expression in colorectal cancer cells in a high-fat environment is obtained through circular RNA sequencing, and exosomes secreted by fat cells are transported and then are taken by the colorectal cancer cells. Clinical samples verify that the expression of the circ-PRKACB in cancer tissues of colorectal cancer patients is higher than that in para-carcinoma tissues, the expression of the circ-PRKACB in serum of colorectal cancer patients is higher than that in serum of non-colorectal cancer patients, the expression quantity is in positive correlation with BMI, and the circ-PRKACB can be used as a biomarker for risk or prognosis evaluation of colorectal cancer. In a mouse colorectal cancer lung metastasis model, circ-PRKACB expression is knocked down, mouse lung metastasis lesions are reduced, the number of survival days is increased, and the circular RNA has the potential of serving as a colorectal cancer treatment target.

The application belongs to the technical field of biological pharmacy, discloses application of RING1 in inhibition of esophageal squamous cell carcinoma metastasis through ubiquitination degradation of Integrin alpha 5, and provides application of a RING1 activator in preparation of a drug for treating metastatic esophageal squamous cell carcinoma. The application systematically evaluates the inhibiting effect of RING1 on esophageal squamous cell carcinoma metastasis through in-vitro cell experiments and a mouse in-vivo metastasis model; the results show that RING1 inhibits the activation of the FAK signal pathway by mediating K11 type ubiquitination degradation of Integrin alpha 5, and then inhibits the adhesion, migration ability and in-vivo metastasis ability of ESCC cells.

The application belongs to the technical field of biological medicine, and relates to an SLC15A1 targeted protein degradation agent, a construction method thereof and application of the agent in preparation of a drug for treating brain metastasis of lung adenocarcinoma. The application constructs an SLC15A1 targeted PROTAC protein degradation agent IL-PROTAC. The degradation agent couples ibuprofen with a ligand of an E3 ubiquitin ligase, lenalidomide, through a linker, so as to form a bifunctional molecule capable of targeting SLC15A1 and inducing protein degradation of SLC15A1. The IL-PROTAC drug constructed by the application has been proved to be capable of significantly inhibiting tumor growth of a LUAD brain metastasis model and prolonging the survival cycle of an animal model.

The invention discloses an establishment method and application of a mouse gastric cancer remote metastasis model, and the establishment method comprises the following steps: injecting a mouse gastric adenocarcinoma cell line MKC1 (Mus musculus) into a mouse body through intraperitoneal injection, portal intravenous injection, spleen injection or caudal intravenous injection, and feeding to obtain the mouse gastric cancer remote metastasis model. Compared with the prior art, the mouse gastric cancer distant metastasis model established in the invention has the advantages of strong repeatability in the construction process and good tumor formation stability, especially can form tumors in the C57BL / 6 mouse body with a sound immune system, and is suitable for research on gastric cancer distant metastasis molecular mechanism, immune microenvironment, chemotherapeutic drug resistance mechanism and the like.

The invention discloses a marker for liver metastasis of breast cancer and application of the marker, and relates to the technical field of biological medicines. The marker is MSLN, and the experimental method of the marker comprises the following steps: S1, constructing a mouse organ metastasis model; s2, separating and culturing primary cells; s3, RNA extraction and qRT-PCR (quantitative reverse transcription-polymerase chain reaction S4, carrying out RNA sequencing analysis; s5, performing a protein immunoblotting experiment; s6, performing immunohistochemical staining; s7, carrying out bioinformatics analysis; and S8, statistical analysis. The invention covers a complete process from mouse model construction, primary cell culture, RNA extraction and qRT-PCR analysis, RNA sequencing analysis, western blot experiment, immunohistochemical staining to bioinformatics analysis and statistical analysis, and provides a systematic and comprehensive technical means for researching the breast cancer hepatometastasis marker MSLN.